An Automated MS Data Workflow Enabling Targeted, Site-Specific N-Glycosylation Monitoring of Biopharmaceuticals
Discover how scientists at Merck addressed the challenges of high-throughput released glycan analysis in increasingly complex fusion proteins by implementing an automated MS-based glycopeptide mapping workflow. Compared to conventional released-glycan analysis methods, such as 2AB-UPLC and CGE-LIF, the advantages of their glycosylation monitoring workflow include:
- The ability to monitor glycosylation at the site-specific, amino-acid level instead of just at the global level
- Higher confidence in automated peak assignment through accurate mass measurement, making co-elution issues a thing of the past
- User-friendly processing of 45 samples in under an hour, instead of the several days of expert manual review that would otherwise be required.